Fortress Biotech's Subsidiary Sells Rare Pediatric Disease Priority Review Voucher for $205 Million

Cyprium Therapeutics, a majority-owned subsidiary of Fortress Biotech, enters into agreement to sell its Rare Pediatric Disease Priority Review Voucher.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million. The voucher was issued upon the FDA approval of Cyprium's drug ZYCUBO (copper histidinate) for the treatment of Menkes disease in pediatric patients.

Why it matters

The sale of the Priority Review Voucher represents a significant financial windfall for Cyprium and its parent company Fortress Biotech. Priority Review Vouchers are valuable assets that can be used to expedite the FDA approval process for future drug candidates, or sold to other pharmaceutical companies. This transaction demonstrates Cyprium's ability to generate value from its drug development programs.

The details

In December 2023, Sentynl Therapeutics, Inc. assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium. The Priority Review Voucher was then immediately transferred to Cyprium following ZYCUBO's FDA approval in January 2026. Cyprium is obligated to pay 20% of the $205 million proceeds from the voucher sale to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

  • ZYCUBO was approved by the FDA on January 12, 2026.
  • Cyprium entered into the asset purchase agreement to sell the Priority Review Voucher in February 2026.

The players

Fortress Biotech, Inc.

An innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders.

Cyprium Therapeutics, Inc.

A majority-owned subsidiary of Fortress Biotech that is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.

Sentynl Therapeutics, Inc.

The company that assumed full responsibility for the development and commercialization of ZYCUBO from Cyprium in December 2023.

Eunice Kennedy Shriver National Institute of Child Health and Human Development

An institute of the National Institutes of Health that Cyprium is obligated to pay 20% of the Priority Review Voucher sale proceeds to.

Lindsay A. Rosenwald, M.D.

Fortress' Chairman, President and Chief Executive Officer, and Cyprium's Chairman.

Got photos? Submit your photos here. ›

What they’re saying

“The recent approval of ZYCUBO was a significant achievement for patients with Menkes disease and the sale of the PRV by Cyprium shows our continued execution in value-generating corporate transactions.”

— Lindsay A. Rosenwald, M.D., Fortress' Chairman, President and Chief Executive Officer and Cyprium's Chairman (Globe Newswire)

“We are very pleased with the recent progress at Cyprium, which includes the approval of ZYCUBO for the treatment of Menkes disease along with the execution of this important agreement.”

— Lung S. Yam, M.D., Ph.D., Cyprium's President and Chief Executive Officer (Globe Newswire)

What’s next

The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.

The takeaway

The sale of Cyprium's Priority Review Voucher for $205 million demonstrates Fortress Biotech's ability to generate significant value from its subsidiary's drug development programs. This transaction provides Cyprium with additional resources to advance its pipeline of therapies for rare diseases like Menkes disease.